Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Enekinragene Inzadenovec (PCRX-201)
Enekinragene Inzadenovec · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A Dose A | EXPERIMENTAL | Single Intra-Articular injection |
| Part A, Placebo | PLACEBO_COMPARATOR | Single Intra-Articular injection |
| Part B Dose A | EXPERIMENTAL | Single Intra-Articular injection |
| Part B Dose B | EXPERIMENTAL | Single Intra-Articular injection |
| Part B Placebo | PLACEBO_COMPARATOR | Part B Placebo |
| Part A, Dose B | EXPERIMENTAL | Single Intra-Articular injection |
| Name | Type | Description |
|---|---|---|
| Enekinragene Inzadenovec (PCRX-201) | BIOLOGICAL | Enekinragene Inzadenovec (PCRX-201) injection |
| Placebo | BIOLOGICAL | Placebo injection |
Inclusion Criteria: * Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions. * Subjects must be male or female and 45 to 80 years old, inclusive, at Screening. * Subjects must exhibit symptoms associated with oste...
Enekinragene Inzadenovec, also known as PCRX-201, is an investigational gene therapy being developed for the treatment of painful osteoarthritis (OA) of the knee. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
Enekinragene Inzadenovec is a gene therapy, classified under the -vec/-gene target class. It is designed to deliver a gene to treat osteoarthritis of the knee, though the specific molecular target is not disclosed in the available information.
Enekinragene Inzadenovec is developed by Pacira BioSciences, Inc., a company traded on the stock exchange under the ticker symbol PCRX. The drug is currently in Phase 2 clinical trials for osteoarthritis of the knee.
Enekinragene Inzadenovec is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being studied for safety and efficacy in patients with painful osteoarthritis of the knee.
Enekinragene Inzadenovec is being studied in a Phase 2 clinical trial with the identifier NCT06884865. This randomized, double-blind, placebo-controlled trial is recruiting 135 participants in the United States to assess the safety and tolerability of the drug in subjects with painful osteoarthritis of the knee.
Yes, Enekinragene Inzadenovec is also known as PCRX-201. Both names refer to the same investigational gene therapy being developed by Pacira BioSciences for the treatment of osteoarthritis of the knee.